| AHRQ / Chou et al. (2021) | Concluded insufficient evidence for pulsed RFA; found CRFA associated with moderate–large short-term pain reduction for SIJ vs sham but evidence beyond 6 months lacking; small sample sizes and short follow-up limit conclusions. |
| Hayes assessments (2019-2024) | Hayes concluded low or very low-quality evidence for pulsed RFA, endoscopic rhizotomy, and CRFA; called for well‑designed RCTs and noted minimal support for Intracept with concerns about study quality and placebo effects. |
| Key RCTs / trials cited (e.g., Kroll 2008, Van Zundert 2007, McCormick 2019, Cohen 2024) | Small RCTs and cohort studies with mixed results: Kroll (2008) found greater improvement with continuous RFA vs pulsed RFA; Van Zundert (2007) showed short-term benefit for pulsed RFA in cervical radicular pain; McCormick (2019) CRFA vs traditional RFA inconclusive due to small sample; Cohen (2024) CRFA superior to standard medical management for SIJ at 3 months. |
| SMART trial (Fischgrund et al. 2018) | Sham‑controlled RCT: 3‑month ODI change — treatment −20.5 points vs sham −15.2; responder (≥10‑point ODI) 75.6% vs 55.3%; improvements sustained in extensions but high crossover and other limitations noted. |
| INTRACEPT trial (Khalil et al. 2019 / Smuck et al. 2021 pooled) | Randomized trial vs standard care: 3‑month mean ODI change −25.3 vs −4.4 (adjusted difference 20.9 points, p<0.001); 74.5% vs 32.7% achieved ≥10‑point ODI improvement; pooled/longer‑term analyses report durable improvements up to 3–5 years with reductions in opioid and interventional use but limited by open‑label design and industry sponsorship. |
| Pooled long‑term outcomes (Khalil 2024; Smuck 2023; McCormick 2024) | Pooled analyses report sustained mean ODI and NPS improvements at 3 and 5 years (e.g., ODI reductions ~31.2 at 3 years, ~28.0 at 5 years), decreased opioid use and health care utilization; limited by open‑label design, sponsorship, and lack of long‑term comparators. |
| Hayes & ECRI assessments | Hayes (2021–2025) found minimal support for Intracept and low‑quality evidence overall; ECRI (2020b updated 2024) found potential benefits for Intracept but too few robust data and recommended blinded multicenter RCTs. |
| Cooled RFA evidence (systematic reviews and RCTs) | AHRQ and Hayes reviews: CRFA may provide short‑term (up to 6–12 months) pain and function benefits for SIJ pain vs sham or standard care, but evidence beyond 6 months is limited and trials vary in technique and quality. |
| Endoscopic rhizotomy evidence (Du 2024, Meloncelli 2020) | Systematic review/meta‑analysis and prospective cohort show possible longer‑term pain reduction vs percutaneous RFA in some studies, but overall evidence insufficient to draw firm safety/effectiveness conclusions; need randomized trials. |
| Cryoablation evidence (Birkenmaier 2007; Staender 2005) | Case series and prospective studies report short‑term pain relief in many patients but high failure rates at 12 months in some series; overall evidence insufficient due to lack of controlled trials. |
| Chemical ablation (Joo 2013) | Small randomized study showed longer median effective period for alcohol ablation vs repeat RFA (24 vs 10.7 months) in recurrent thoracolumbar facet pain, but sample size small and evidence limited. |
| Laser ablation (Iwatsuki 2007) | Small case series reported substantial pain reduction at 1 year in many patients but limited by small sample and lack of controls; overall evidence insufficient. |
| Key cohort/case‑series supporting CRFA and cooled devices (Tinnirello 2017; Stelzer 2013; Sun 2018 meta‑analysis) | Observational data and meta‑analyses suggest CRFA can reduce pain and disability for SIJ pain, with some studies showing greater and more durable effects vs conventional devices; limitations include observational design and few controlled trials. |
| BVN systematic reviews (Conger 2021; Nwosu 2023; Mekhail 2023) | Systematic reviews report moderate‑quality evidence that BVN RFA is effective for CLBP with Modic type 1/2 changes (3‑month ≥50% pain reduction 45%–63%; ODI ≥10‑point improvement 75%–93%) but call for more non‑industry, high‑quality trials. |
| Community practice and small series (Schnapp 2023) | Small community practice series showed clinically meaningful ODI and VAS improvements at 1–6 months, but findings limited by small size and lack of controls. |
| Device and coding / FDA and CPT notes | RFA is a procedure (devices regulated by FDA); relevant CPT/unlisted codes and product codes for RFA devices are listed (e.g., 22899, 64628, 64629, 64999; FDA product codes GXD, GXI, GEI). |
| Policy coverage stance | Policy lists pulsed RFA, endoscopic rhizotomy, cryoablation, cooled RFA, chemical and laser ablation, sacroiliac ablation, and intraosseous BVNA as unproven/not medically necessary due to insufficient evidence of efficacy, while summarizing the available positive but limited evidence for BVNA and CRFA. |